LIK066 + Placebo

Phase 2Completed

0 views this week 0 watching💤 Quiet

Interest: 35/100

Hype Score

Development Stage

✓

Pre-clinical

✓

Phase 1

Phase 2

Phase 3

Approved

Indication / Disease

Polycystic Ovary Syndrome

Conditions

Polycystic Ovary Syndrome

Trial Timeline

Jul 24, 2017 → Jun 25, 2018

NCT ID

NCT03152591

About LIK066 + Placebo

LIK066 + Placebo is a phase 2 stage product being developed by Novartis for Polycystic Ovary Syndrome. The current trial status is completed. This product is registered under clinical trial identifier NCT03152591. Target conditions include Polycystic Ovary Syndrome.

What happened to similar drugs?

3 of 14 similar drugs in Polycystic Ovary Syndrome were approved

Approved (3) Terminated (4) Active (7)

✅tredaptive (nicotinic acid/ laropiprant) + placeboMerckApproved

✅Placebo + EverolimusNovartisApproved

✅3 mg DRSP/20 μg EEBayerApproved

🔄Metformin XR + Saxagliptin + Saxagliptin-Metformin XRAstraZenecaPhase 3

🔄Exenatide once weekly (EQW ) + Dapagliflozin (DAPA) + EQW plus DAPA + Dapagliflozin plus Glucophage (MET ER) + Phentermine /Topiramate (PHEN/ TPM) ERAstraZenecaPhase 3

🔄Lisinopril + Telmisartan + PlaceboMerckPhase 3

Hype Score Breakdown

Clinical

Activity

Company

Novelty

Community

Clinical Trials (7)

NCT ID	Phase	Status	Start	Completion	Indication
NCT03320941	Phase 2	Completed	Dec 7, 2017	Jul 25, 2018	Obesity
NCT03205150	Phase 2	Completed	Oct 4, 2017	Nov 14, 2019	Obese Patients With Non-alcoholic Steatohepatitis (NASH)
NCT03152591	Phase 2	Completed	Jul 24, 2017	Jun 25, 2018	Polycystic Ovary Syndrome
NCT03100058	Phase 2	Completed	May 6, 2017	Aug 2, 2018	Obesity
NCT02470403	Phase 2	Completed	Jun 5, 2015	Apr 4, 2016	Elevated Body Mass Index
NCT01915849	Phase 1/2	Completed	Jul 1, 2013	Jan 1, 2014	Type 2 Diabetes Mellitus
NCT01407003	Phase 1/2	Completed	Jun 1, 2011	Feb 1, 2013	Type 2 Diabetes Mellitus (T2DM)

Competing Products

20 competing products in Polycystic Ovary Syndrome

See all competitors

Product	Company	Stage	Hype Score
Tildacerfont + Placebo	Spruce Biosciences	Phase 2	17
ABBV-CLS-628 + Placebo	AbbVie	Phase 2	42
Elagolix + Placebo	AbbVie	Phase 2	35
Metformin XR + Saxagliptin + Saxagliptin-Metformin XR	AstraZeneca	Phase 3	40
Exenatide once weekly (EQW ) + Dapagliflozin (DAPA) + EQW plus DAPA + Dapagliflozin plus Glucophage (MET ER) + Phentermine /Topiramate (PHEN/ TPM) ER	AstraZeneca	Phase 3	40
AZD1613 - Part A + Placebo - Part A + AZD1613 - Part B + Placebo - Part B	AstraZeneca	Phase 1	36
AZD4901 (oral) + Placebo to match AZD4901	AstraZeneca	Phase 2	35
IVF Antagonist Protocol	Merck	Pre-clinical	22
tredaptive (nicotinic acid/ laropiprant) + placebo	Merck	Approved	43
Lisinopril + Telmisartan + Placebo	Merck	Phase 3	40
Lisinopril + Telmisartan + Placebo	Merck	Phase 3	40
Cetrorelix acetate + Cetrorelix acetate + Recombinant Human Choriogonadotropin (r-hCG) + Recombinant human follicle stimulating hormone (r-hFSH)	Merck	Phase 3	40
Gonal-f® + Long GnRH agonist + GnRH antagonist	Merck	Pre-clinical	26
Placebo + Everolimus	Novartis	Approved	43
Octreotide + Placebo	Novartis	Phase 2/3	38
Everolimus + Calcineurin inhibitors maintenance	Novartis	Phase 3	40
Everolimus + Octreotide LAR	Novartis	Phase 2	35
Atorvastatin + Placebo	Pfizer	Pre-clinical	26
Rapamune	Pfizer	Phase 1/2	32
Sirolimus	Pfizer	Phase 2/3	34